

#### Chronological study of infection, seroconversion and associated lung lesions in vaccinated and non-vaccinated pigs

M. Sibila, M. Nofrarías, S. López-Soria, J. Segalés, O. Valero, A. Espinal, M. Calsamiglia

#### ► To cite this version:

M. Sibila, M. Nofrarías, S. López-Soria, J. Segalés, O. Valero, et al.. Chronological study of infection, seroconversion and associated lung lesions in vaccinated and non-vaccinated pigs. Veterinary Microbiology, 2007, 122 (1-2), pp.97. 10.1016/j.vetmic.2007.01.010 . hal-00532194

#### HAL Id: hal-00532194 https://hal.science/hal-00532194v1

Submitted on 4 Nov 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

#### Accepted Manuscript

Title: Chronological study of *Mycoplasma hyopneumoniae* infection, seroconversion and associated lung lesions in vaccinated and non-vaccinated pigs

Authors: M. Sibila, M. Nofrarías, S. López-Soria, J. Segalés, O. Valero, A. Espinal, M. Calsamiglia

PII:	\$0378-1135(07)00033-8
DOI:	doi:10.1016/j.vetmic.2007.01.010
Reference:	VETMIC 3564
To appear in:	VETMIC
Received date:	2-11-2006
Revised date:	8-1-2007
Accepted date:	12-1-2007



Please cite this article as: Sibila, M., Nofrarías, M., López-Soria, S., Segalés, J., Valero, O., Espinal, A., Calsamiglia, M., Chronological study of *Mycoplasma hyopneumoniae* infection, seroconversion and associated lung lesions in vaccinated and non-vaccinated pigs, *Veterinary Microbiology* (2007), doi:10.1016/j.vetmic.2007.01.010

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1	CHRONOLOGICAL STUDY OF MYCOPLASMA HYOPNEUMONIAE
2	INFECTION, SEROCONVERSION AND ASSOCIATED LUNG LESIONS IN
3	VACCINATED AND NON-VACCINATED PIGS
4	
5	M. Sibila <sup>a</sup> , M. Nofrarías <sup>a</sup> , S. López-Soria <sup>a</sup> , J. Segalés <sup>a</sup> , O. Valero <sup>b</sup> , A. Espinal <sup>b</sup> , M. Calsamiglia <sup>a</sup>
6	
7	<sup>a</sup> Centre de Recerca en Sanitat Animal (CReSA) - Departament de Sanitat i d'Anatomia
8	Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, Spain. <sup>b</sup> Servei
9	d'Estadística, Universitat Autònoma de Barcelona, Spain.
10	
11	
12	
13	
14	
15	
16	
17	
18	Corresponding Author:
19	<i>Tel:</i> 34-935814495
20	Fax: 34-93-5814490
21	E.mail address: marina.sibila@cresa.uab.es

#### 22 Abstract:

23 A field trial was conducted to study Mycoplasma hyopneumoniae (Mh) infection 24 dynamics by nested polymerase chain reaction (nPCR) and serology in pigs of a farm 25 affected by enzottic pneumonia (EP). Moreover, correlation of Mh detection at 26 different respiratory tract sites with presence of EP gross and microscopic lung lesions was assessed. These parameters were studied and compared between vaccinated (two 27 28 doses at 1 and 3 weeks of age versus one dose at 6 weeks of age) and non-vaccinated 29 pigs. Animals were monitored from birth to slaughter by nPCR from nasal swabs and by 30 serology. From 3 to 22 weeks of age, an average of 3 pigs per treatment and per batch 31 were necropsied (n=302). The remaining pigs were sent to the slaughter (n=103). Nasal, 32 bronchial and tonsillar swabs were taken from the necropsied/slaughtered pigs; gross 33 and microscopic EP-suggestive lung lesions were also assessed. Single and double 34 vaccination resulted in earlier seroconversion and higher percentage of Mh seropositive 35 pigs compared to control group. At slaughter, double vaccinated pigs showed lower 36 percentage of EP-compatible gross lung lesions and lower Mh prevalence at upper 37 respiratory tract sites (nasal cavity and tonsil) than control pigs.

38

39 Keywords: Mycoplasma hyopneumoniae; infection; lesions; serology; vaccination

40

#### 41 **1. Introduction**

*Mycoplasma hyopneumoniae* (Mh) is the etiologic agent of enzootic pneumonia (EP) in pigs, a chronic respiratory disease that causes major economic losses to the pig industry (Thacker, 2006). Detrimental effects of EP are mainly associated to treatment costs, reduced performance in growing and finishing pigs and the consequent lower market price of the carcass. The decrease in average daily gain and the lower carcass weight is correlated with the increase of pneumonic lung lesions (Pommier et al., 2000).

48 Vaccination with commercial bacterins is one of the tools used to ameliorate the 49 effects of Mh infection. Major advantages of Mh vaccination include improvement of 50 production parameters, shorter time to reach slaughter weight, reduction of clinical 51 signs and lung lesions and, occasionally, lower mortality and improvement of carcass 52 quality (Haesebrouck et al., 2004). Traditional Mh vaccination protocols include two 53 doses of bacterin, although the use of one shot vaccines is nowadays commercialized as 54 well (Baccaro et al., 2005). Vaccination with a single-dose bacterin dose has the main 55 advantage of reducing labour and causing less stress to the animals (Baccaro et al., 56 2005; Dawson et al., 2002).

The efficacy of one or two doses of Mh vaccination varies depending on the commercial vaccine product, schedule, farm type and the study design used (Andreasen et al., 2001; Dawson et al., 2002; Kyriakis et al., 2001; Pallares et al., 2000; Ruiz et al., 2002). Most of published field studies have measured the effect of vaccination against Mh on lung lesion reduction and improvement of production parameters, but few of them have addressed Mh infection dynamics (Baccaro et al., 2005; Martelli et al., 2006; Ruiz et al., 2002).

64 Therefore, the objectives of the present work were: 1) to study Mh infection 65 dynamics by nPCR and serology in pigs of a farm affected by EP, and 2) to correlate

66 Mh detection at different respiratory sites with presence of EP gross and microscopic 67 lung lesions in the same farm. These parameters were studied and compared in pigs 68 vaccinated with two and one dose of a commercial bacterin and with non-vaccinated 69 pigs.

70

#### 71 **2. Materials and methods**

72 2.1 Farm

73 A one site farrow-to-finish herd with 240 sows and continuous flow production 74 system (in nursery and finishing units) was selected. The farm had respiratory clinical 75 signs in fattening pigs (coughing) and EP-compatible lung lesions at slaughter. To 76 confirm Mh-related disease, a nPCR from nasal swabs and evaluation of gross lung 77 lesions from 34 slaughtered pigs were performed. Moreover, blood samples from other 78 21 slaughtered pigs were also taken. All 34 (100%) tested pigs were positive to Mh by 79 nPCR and had a mean macroscopic lung score of 9.16 based on the classification by 80 Hannan et al. (Hannan et al., 1982). On the other hand, 13 out of 21 (62%) were 81 seropositive to Mh.

82

#### 83 *2.2 Study design*

This was a blinded, randomized and controlled field trial. A total of 542 pigs (268 female and 274 male) from 69 different sows of 6 different farrowing batches were included in this study. The parity range of selected sows was from 1 (n=5) to 8 (n=2), with a mean of 4.4 parity number. No Mh vaccination or medication protocols were being performed before the start of the study. Piglets were ear-tagged at 1 week of age and randomly distributed in the following treatment groups: 1) Two dose group (n=182): pigs that received 2 ml of vaccine at 1 and 3 weeks of age and 2 ml of

91 phosphate buffer saline (PBS) at 6 weeks of age; 2) One dose group (n=176): pigs 92 injected with 2 ml of PBS at 1 and 3 weeks of age and 2 ml of vaccine at 6 weeks of 93 age; 3) Control group (n=184): pigs that received 2 ml of PBS at 1, 3 and 6 weeks of 94 age. In order to distribute animals to different treatment groups, piglets from one sow 95 were assigned correlatively to the 3 treatments: first randomly selected piglet was 96 assigned to "two doses of vaccine" treatment, second piglet to "one dose of vaccine" 97 treatment and the third one to the control group. This criterion was followed until each 98 piglet from the same sow was assigned to one out of 3 treatments. Afterwards piglets 99 from the next sow were distributed continuing the treatment order from the previous 100 sow. All vaccinations, as well as injections of PBS, were administered intramuscularly 101 according to the recommendations of the manufacturer. The vaccine product used was a 102 commercial batch (lot 5JZ2) of MYPRAVAC SUIS® (Hipra [Girona] Spain), which is a 103 suspension of inactivated Mh strain J with a carbomer/levamisol adjuvant. Using this 104 treatment design, all piglets received the same number of injections. To minimize the 105 potential litter effect on Mh vaccination, each litter had 2 to 3 pigs of each treatment. To 106 avoid deviations due to management or facilities conditions, a similar number of 107 animals of each treatment group were included in all pens.

Piglets were all housed in similar conditions, received the same feed and were subjected to the same management practices (castration, iron injection, teeth clipping and tail docking). Animals were weaned at 17 to 23 days of age and transferred to the nursery units, where litters from different sows were mixed. At 9 weeks of age, pigs were moved to the growing-finishing units and they were distributed taking into account the body condition, following the farmer criteria. All three treatments were represented in each pen in both, nursery and growing-finishing barns. Treatments, housing,

- husbandry and slaughtering conditions conformed to the European Union Guidelinesand Good Clinical Practices.
- 117

#### 118 2.3 Sample collection

Nasal swabs (Culturette TM, Becton Dickinson, Sparks, USA) and blood samples (5 ml
Venoject, Terumo Europe, Madrid, Spain) from all animals were taken at 1, 3, 6, 9, 12,
15, 18, 22 and 25 weeks of age. Nasal swabs were obtained by swabbing the nasal
mucosa of both nostrils reaching deeply into turbinates. Moreover, blood sample from
sows was collected at 1 week post-farrowing (the same day as piglet sampling at 1
weeks of age).

125 The initial number of pigs included in the study (n=542) decreased over time 126 because, from 3 weeks of age onwards, necropsies of randomly selected pigs of each 127 treatment were performed. To select these animals, a random table was done taking into 128 account that animals from different treatments and sows were represented in each necropsy day. Thus, an average of 3 pigs per treatment and batch were necropsied at 3 129 130 (n=39), 6 (n=36), 9 (n=37), 12 (n=37), 15 (n=48), 18 (n=51) and 22 (n=54) weeks of 131 age (total of 302 pigs). Necropsied pigs were euthanized with an intravenous overdose 132 of sodium pentobarbital. Pigs that reached the market weight were slaughtered at 25-28 133 weeks of age (n=103). From the 542 animals initially included in the study, 50 (9.2%) 134 nursery piglets died due to central nervous clinical signs probably associated to 135 Streptococcus suis infection. On the other hand, 71 (13%) growing and finishing pigs 136 died due to mainly respiratory and wasting problems. Specific diagnosis of each dead 137 pig was not recorded since the farm was visited only the sampling days. Therefore, 138 performing the necropsy of death animals was not possible. Moreover, there were 16

finishing pigs that lost the ear-tag at slaughter. From that 16 (3%) pigs data recordedarrived until 22 weeks of age.

141 From the necropsied (n=02) and slaughtered (n=102) pigs, tonsillar and 142 bronchial swabs (Culturette TM, Becton Dickinson, Sparks, USA) and lung tissue were 143 taken. Tonsillar swabs were obtained by swabbing the surface of the tonsil thoroughly 144 but gently. Bronchial swabs and lung samples were obtained from the lungs already 145 separated from the carcass; samples were taken from cranial and middle lobes and from 146 pneumonic areas when present. Afterwards, these tissue pieces were fixed by immersion 147 in 10% buffered formalin. All collected samples were individually identified and 148 transported (swabs and blood samples in refrigeration) to the laboratory, where they 149 were stored at -80°C until their processing.

150

#### 151 2.4 DNA extraction and nPCR to detect Mh nucleic acid.

Nasal, tonsillar and bronchial swabs were resuspended in 1 ml of sterile PBS and vigorously vortexed. Four hundred microliters of the suspension were used for DNA extraction. DNA was extracted using a commercial kit (Nucleospin® Blood, Macherey-Nagel GmbH & Co KG Düren, Germany) and samples were processed according to manufacturer's instructions. To test for potential contaminations during the extraction procedure, a negative control was included using PBS as extraction substrate in each group of extracted samples.

A nPCR to detect Mh was performed using previously described primers and conditions (Calsamiglia et al., 1999). To minimize the risk of contaminations, each stage of the nPCR process (DNA extraction, DNA amplification and electrophoresis) was carried out in three separated rooms. In each nPCR reaction, a negative control (consisting of millipore water) every four test samples as well as a positive control

### MANUSCRI

- 164 (DNA extracted from a pure culture of Mh) in the last position were included. The 165 amplified products (352 bp) were run in a 2% agarose gel with 0.05 mg/ml of ethidium
- 166 bromide, and then visualized and pictured (Bio-1d V.96, Vilber Lourmat, France).
- 167
- 168 2.5 ELISA technique to detect Mh antibodies

169 Blood samples were centrifuged at 760 g during 10 minutes at 4°C and the sera 170 obtained were frozen at -80°C until used. Presence of antibodies to Mh was tested by a 171 monoclonal blocking ELISA (CIVTEST SUIS® MYCOPLASMA 172 HYOPNEUMONIAE, HIPRA [Girona], Spain). The sensibility and specificity of the 173 test used were, 93% and 96% respectively (Sorensen et al., 1992). The inhibition 174 percentage (IP) was calculated taking into account the optical densities (OD) of each 175 sample as well as the one of the negative control (negative value). ELISA results 176 interpretation, based on IP values, was as follows: IP < 50%, negative; IP > 50%, 177 positive. This percentage was obtained from the following formula:

- 178

Mean negative value OD - sample OD

- \_\_\_\_\_X 100 179 IP(%) =
- 180

#### Mean negative value OD

181 In addition, sera from slaughtered pigs (n=102, serum from one animal was 182 lacking) were tested for antibodies to: porcine respiratory and reproductive syndrome 183 virus (PRRSV) (indirect ELISA, CIVTEST SUIS PRRS® European variant, Hipra; 184 interpretation: positive >20); H1N1, H3N2 or H1N2 subtypes of swine influenza virus 185 (SIV) (indirect ELISA, CIVTEST SUIS Influenza®, Hipra; interpretation: positive 186 >20); Aujeszky's disease virus (ADV) (blocking ELISA, CIVTEST SUIS ADV®, 187 Hipra, interpretation: positive >90); and Actinobacillus pleuropneumoniae (indirect 188 ELISA, CIVTEST SUIS App<sup>®</sup>, Hipra, interpretation: positive >20).

189

#### 190 2.6 Pathological studies

Extension of EP-compatible gross lesions (craneo-ventral pulmonary consolidation) was assessed taking into account the localization of the lesions and the relative volume of each lobe (Hannan et al., 1982). EP-compatible macroscopic lung lesions were registered on a lungs' diagram and given from 1 to 5 points per lobe depending on the extension of these lesions. The maximum total score possible per lung was 35. Once given the lesional scoring per lobe, the scoring was normalized taking into account the relative volume of each lobe (Hannan et al., 1982).

198 After fixation for 24 h in 10% buffered formalin, lung pieces were dehydrated, 199 paraffin embedded, sectioned at 4 µm and stained with haematoxylin and eosin for 200 histological examination using a light microscope. Histopathologic lesions were graded 201 from 0 to 4, following previously described criteria (Calsamiglia et al., 2000). Absence 202 of lesions scored 0. Lesions characterized by inflammation non suggestive of EP were 203 scored 1 and 2; scores 3 and 4 were considered suggestive of Mh infection. Score 3 204 consisted of lesions with perivascular and peribronchiolar lymphoplasmacytic 205 hyperplasia, pneumocyte type II hyperplasia and edema fluid in the alveolar spaces with 206 neutrophils, macrophages and plasma cells. Score 4 was considered when lesions with 207 the characteristics of score 3 together with the presence of evident peribronchial and 208 perivascular lymphoid follicles. Lung tissue scoring was performed in a blinded fashion. 209 In the statistical analysis this variable was categorized in two groups: presence of non-210 suggestive (0, 1 or 2 histopathologic scores) and suggestive (3 or 4 histopathologic 211 scores) EP microscopic lung lesions.

212

213 2.7 Statistical analyses

Bivariate analyses using contingency tables (Chi-square statistics or Fisher's exact test for 2x2 tables) were used to compare following parameters among different treatments groups: 1) number of seropositive sows 2) nPCR Mh detection at nasal swabs at different sampling weeks; 3) nPCR Mh detection in three respiratory sites at necropsy or slaughter age; 4) Mh antibodies detection by ELISA at different sampling weeks; and 5) microscopic lung lesion scoring globally (including all ages studied within a group) and by necropsy age.

Non-parametric statistical analysis (Kruskal-Wallis statistic) was used for testing differences in gross lung lesion scoring among animals from different treatments groups. On the other hand, Wilcoxon statistics were used to assess the relationship between: 1) gross lung lesion scoring and detection of the pathogen in the three different sampling sites in the necropsied (n=302) and slaughtered (n=103) pigs; and 2) gross lung lesion scoring at slaughter (n=103) with nPCR results in nasal cavities at different sampling times (3, 6, 9, 12, 15, 18, and 22 weeks of age).

Statistical analyses were performed with the SAS system for windows version 8.0 (SAS Institute Inc, Cary, North Carolina, USA). Statistical significance level was set at  $\alpha$ =0.05.

The vaccine efficacy in reducing lung score was calculated, using group median lung scores (Jones et al., 2005), as follows: Vaccine efficacy = [(median non-vaccinated group score – median vaccinated group score)/ median non-vaccinated group score] x 100.

235

236 **3. Results** 

From the 69 sows included in this study, 20 (29%) were seropositive at 1 week
post-farrowing. No statistical significant differences between numbers of seropositive

239 sows neither per treatment nor per parity number were found. On the contrary, sow 240 parity number was significantly associated with serologic status of piglets at 1 one week 241 of age (p=0.006). At that age, all piglets (n=35) coming from gilts (n=5) were Mh 242 seronegative. Nevertheless, it should be taken into account that the five gilts included 243 in this study were seronegative. On the other hand, sow parity number was also 244 significantly related with detection of Mh in their piglets by PCR at 9 (p=0.003) and 12 245 (p=0.0004) weeks of age. Specifically, was detected in higher percentages in piglets 246 coming from gilts (5 out of 24 [20.8%] and 12 out 19 [63.1%] at 9 and 12 weeks of age 247 respectively) than from sows of intermediate (12 out of 263 [4.5%] and 69 out 220 248 [31.3%], at 9 and 12 weeks of age respectively) or high (11 out of 105 [10.4%] and 18 249 out 94 [19.1%], at 9 and 12 weeks of age respectively) parity number.

250 Globally, Mh nPCR detection percentages at nasal cavities were very similar in 251 all three treatment groups (Table 1). From 1 to 9 weeks of age, Mh was detected in 252 nasal cavities in relatively low proportion (<10%) in all groups. On the contrary, Mh 253 detection percentages tended to increase in all three treatments groups from 12 weeks of 254 age until the slaughter age. At 6 weeks of age, there were higher percentages of pigs 255 positive by nPCR in one dose group than the control group of pigs (p < 0.05). 256 Moreover, at slaughter age, percentage of nPCR positive pigs at nasal cavities was 257 higher in the group of animals that received two doses of vaccine than in control pigs (p 258 < 0.05).

259 Mh serological results from all tested pigs are summarized in Figure 1. A similar 260 percentage of seropositive pigs was observed in all treatments groups at 1 and 3 weeks 261 of age. After the decrease of this initial percentage, an earlier seroconversion to Mh was 262 observed in vaccinated groups compared with non-vaccinated pigs. Significant 263 differences between treatments regarding the percentage of Mh seropositive pigs were

11

observed at 6 (two dose versus one dose and control groups), 9 (two dose versus control
groups) and from 12 to 22 (both vaccinated groups versus control groups) weeks of age.
At slaughter age, percentages of seropositive pigs to Mh were not different between
treatment groups.

From 542 pigs included in this study, 405 (135 for the two doses treatment, 133 for the one dose treatment, and 137 for the control group control treatment) were necropsied/slaughtered at different sampling times. From these 405 animals, 4 nasal swabs, 4 bronchial swabs, and 4 tonsillar swabs were missing.

272 Overall, Mh was detected in greater percentages in bronchial (227/401, 56.1%) 273 followed by tonsillar (136/401, 33.9%) and nasal swabs (122/401, 30.4%). Moreover, 274 detection of Mh at bronchus by nPCR had a relationship with detection at nasal cavity 275 (p<0.05) and tonsil (p<0.05) swabs; detection of Mh DNA at tonsillar had also a 276 relationship with nasal swabs (p<0.05). Results of nPCR detection at nasal cavity, 277 bronchus and tonsil of necropsied pigs at different ages are summarized in Tables 2, 3 278 and 4. Mh detection at nasal, bronchial and tonsillar swabs from necropsied/slaughtered 279 pigs was lower than 10% in all treatments groups from 1 to 9 weeks of age. Percentage 280 of bronchial nPCR positive pigs increased by 12 weeks of age, and it was maintained 281 high until slaughter age where aproximately an 80% of the pigs were positive by nPCR. 282 On the contrary, Mh detection in nasal cavity and tonsil showed a soft peak at 15 weeks 283 of age in all studied groups, followed by an irregular profile. At slaughter age, control 284 group had greater percentage of Mh detection at nasal cavity and tonsil than pigs 285 vaccinated with two doses of bacterin (p=0.0128 and p=0.0082, respectively).

Pulmonary consolidation suggestive of EP was observed in a number of necropsied animals. From a total of 404 pigs, 124 (30.6%) had no macroscopic lung lesions, 221 (54.7%) had less than 25% (8.75 out of 35 scoring points) affected lung

289 affected, 36 (8.9%) showed between 25 to 50% (17.5 out of 35 scoring points) damaged 290 lung, 18 (4.5%) with 50 to 75% (26.25 out of 35 scoring points) lung affected and, 291 finally, 5 (1.2%) had more than 75% of the lung affected. No gross lung lesions 292 compatible with EP were assessed in one pig due to a severe, diffuse fibrous pleuritis 293 observed at the moment of necropsy. Although EP-compatible gross lung lesions 294 (pulmonary craneo-ventral consolidation) were observed in animals of different ages 295 and treatments, the extension of these lesions increased at 12-15 weeks of age onwards 296 (Table 5). At 25 weeks of age, median lesional scores were lower in two-dose 297 vaccinated pigs (score value of 2.18) and one-dose vaccinated animals (score value of 298 2.42) compared to control pigs (score value of 5.70); however, only significant 299 differences (p=0.05) were confirmed between the two dose and the control groups. 300 Vaccine efficacy in reducing lung lesions score was 61.8% and 57.8% when comparing 301 two and one dose vaccination groups, respectively, with controls animals.

302 Overall, EP gross lung lesions were associated with prevalence of Mh in nasal 303 cavity, tonsil and bronchus (Table 6) at the necropsy or slaughter age; median EP-304 compatible lung scores were higher (p < 0.05) in pigs positive by nPCR than negative 305 ones, independently of the treatment received. Moreover, in the animals send to the 306 slaughter (n=103), an association of the average lesional scores with nPCR detection in 307 nasal swabs at 3 (p=0.057, Chi-square value 3.64) weeks of age was seen; in other 308 words, animals with a positive nPCR nasal swab at 3 weeks of age (n=7) tend to have 309 higher median EP-compatible lung lesions (5.0 ranging from 2.4 to 25) at slaughter age 310 than pigs with a negative result (n=96, 2.7 ranging from 0 to 28).

From the 405 necropsied/slaughtered pigs, 63 (15.5%) did not have any microscospic lung lesions (score 0), 94 (23.2%) showed EP non-suggestive microscopic lung lesions (scores 1 or 2) and 248 (61.2%) showed EP suggestive microscopic lung

lesions (scores 3 or 4). Percentage of pigs showing these lesions increased with the age
in all three treatments groups (Table 7). No statistically significant differences on EP
suggestive microscopic lung lesions were observed between the studied groups in a
given age.

Percentage of seropositive pigs at slaughter to PRRSV, ADV, SIV and *A. pleuropneumoniae* were 100, 90, 81 and 39%, respectively. No significant differences on percentages of seropositive pigs to these respiratory pathogens (data not shown) were detected among treatment groups. However, control pigs (n=35) showed a statistically significant higher (p=0.02) serologic values against PRRSV (164.6  $\pm$  27.8) than pigs vaccinated with two (140.6  $\pm$  48.8) and one dose (141.2  $\pm$  40.8) of bacterin.

324

#### 325 **4. Discussion**

The present study describes the pattern of Mh infection and seroconversion in vaccinated and non-vaccinated pigs in a farrow-to-finish operation with EP associated clinical signs. Monitoring pigs from birth to slaughter with sequential necropsies every weeks allowed understanding the effect of different vaccination schedules on localization of Mh in different respiratory tract sites and EP lung lesion evolution.

Differences in EP-compatible lung lesion scores were observed at slaughter age 331 332 between double vaccinated and control pigs, coinciding with other field trials in which 333 the same (Llopart et al., 2002) or other (Kyriakis et al., 2001; Maes et al., 1999; 334 Pommier et al., 2000) commercial two-dose vaccines were administered at weaning age. 335 Traditionally, percentage of lung lesion reduction in vaccinated pigs compared to 336 control pigs is one of the main parameters used to measure Mh vaccine efficacy (Jones 337 et al., 2005). In the present study, vaccination at 1 and 3 weeks of age resulted in a 338 reduction of EP-compatible gross lung lesions of nearly 62% when compared to the

339 controls pigs. Similar or lower lung lesion reduction has been also found in other field 340 studies using two doses of Mh vaccine (Kyriakis et al., 2001; Maes et al., 1999; Scheidt 341 et al., 1994). On the other hand, single vaccination at 6 weeks of age resulted in 57.8% 342 lung lesion reduction; however, the extent of these lesions were not statistical 343 significantly different from the control group, probably due to relatively low mean lung 344 lesional score observed (4.17 versus 7.71, respectively). Obtained results for single Mh 345 vaccination are in the same line than those achieved in other studies (Baccaro et al., 346 2005; Dawson et al., 2002) in which vaccination was performed at weaning age. On the 347 contrary, two field studies in which one dose vaccine was administered at 10 weeks of 348 age (Kyriakis et al., 2001; Pommier et al., 2000) found relatively low (<20%) lung 349 lesion reduction, probably due to the short time between vaccine application and timing 350 of infection. In the present study, single vaccination was administered approximately 6 351 to 9 weeks before most of the pigs had Mh at bronchus, suggesting that pigs had enough 352 time to develop a protective immune response able to reduce the extent of gross lung 353 lesions.

354 Increase of percentage of animals showing EP-compatible macroscopic lesions 355 coincided with the increase of Mh detection at all three respiratory sites (12-15 weeks of 356 age) but not with the increase of percentage of pigs showing EP-suggestive microscopic 357 lung lesions, which occurred earlier (6-9 weeks of age). This coincidence on time 358 between infection and macroscopic lung lesions but not with microscopic ones, suggest 359 that these latter lesions might be caused by other pathogens different from Mh, such as 360 SIV (Thacker et al., 2001). In fact, seroconversion against SIV was detected in 361 slaughtered pigs of these groups, indicating that this virus had circulated in that unit. 362 However, the detection of microscopic lesions before the observation of gross lesions 363 would also suggest initial phases of Mh lung colonization

The fact that EP clinical signs (mainly coughing) at individual level in this study were not recorded, prevent us from knowing the number of animals showing clinical signs as well as the exact time of disease appearance and its relationship with lung lesions evolution.

The fact that the percentage of seropositive sows was not different among treatments, and that the percentage of seropositive pigs at 1 and 3 weeks of age was similar in all treatments, suggest that in the conditions of this study, there were no influence of sow serologic status on the response to the treatment of piglets.

The statistical association between gilt serology and seronegative pigs at 1 week of age is explained by the lack of seropositive gilts included in the study. On the other hand, the fact that all piglets from these gilts were seronegative and had greater probabilities of being infected by Mh at 6 and 9 weeks of age, may suggest a beneficial effect of maternal derived antibodies against *Mh* colonization.

377 Under field conditions, seroconversion to Mh is usually guite delayed and occurs 378 mainly in growing and finishing units (Leon et al., 2001). In the present study, 379 seroconversion was observed 3 weeks before in both vaccinated groups (between 9 to 380 12 weeks of age) than in control animals (between 12 to 15 weeks of age). Both 381 vaccination groups had a very similar serumprofile, only differing statistically at 6 382 weeks of age. At that week, percentage of seropositive pigs in the two dose group did 383 not decline to the low percentage as the one dose group did, indicating a humoral 384 immune response due to vaccination. On the other hand, at 12 weeks of age, percentage 385 of seropositive pigs from one dose group reached nearly the same percentage as the two 386 dose group (21 and 23%, respectively). Therefore, obtained results indicated the 387 capability of both vaccine schedules to elicit a detectable humoral immune response to 388 Mh after vaccination.

389 Percentage of seropositive pigs increased progressively towards the end of the 390 finishing period in all three groups, indicating that both vaccinated and non-vaccinated 391 pigs produced also a humoral detectable response to natural infection. In this study, Mh 392 was detected at upper respiratory tract levels (nasal cavity and tonsil) and at the site of 393 pathogen's action, the bronchus (Thacker, 2006), confirming previous published results 394 (Sibila et al., 2004). Bacterioprofiles obtained in the present work indicated that, 395 although most pigs became infected in the fattening units. Mh early colonization did 396 sporadically occur at upper and lower respiratory sites (Baccaro et al., 2005; Sibila et 397 al., 2006).

398 Detection of the pathogen in all treatment groups and ages confirmed that Mh 399 vaccination did not prevent from infection (Maes et al., 1999); however, vaccination 400 was related with a lower Mh prevalence at slaughter age in upper respiratory airways 401 (nasal cavities and tonsils), as previously described (Baccaro et al., 2005; Ruiz et al., 402 2002). This result is probably due to a reduction of Mh excretion (Baccaro et al., 2005). 403 The fact that no differences in Mh prevalence at bronchus were observed may be related 404 to the qualitative technique used to detect this pathogen. It is possible that vaccinated 405 pigs may have lower Mh load at bronchus and, consequently, may shed less pathogen 406 particles (detectable at the upper respiratory tract) than control pigs. A quantitative 407 method for Mh detection would help to confirm if vaccination reduces bacterial load at 408 bronchus, as previously found by culture of the mycoplasma (Okada et al., 1999).

An interesting point to remark was the association between the nasal detection of Mh at weaning with presence of EP-compatible gross lung lesions in the animals slaughtered. These results are in agreement with Fano et al. (Fano et al., 2006) who suggested that prevalence of Mh at nasal cavities of weaning pigs may be an indicator of EP-compatible lung lesions presence at slaughter-age.

415 pathogens (bacterial and/or viral) were also present in this herd. Concomitant presence 416 of PRRSV, ADV, SIV and/or A. pleuropneumoniae in Mh infected herds has also been 417 reported (Maes et al., 1999; Mateusen et al., 2001). In fact, Maes et al. (Maes et al., 418 1999) reported a significantly lower PRRSV seroprevalence in Mh vaccinated pigs. In 419 the present study, differences in PRRSV seroprevalence were not observed between Mh vaccinated and non-vaccinated pigs; however, a reduction of serologic response to 420 421 PRRSV in both vaccinated groups was observed. Although a certain protective effect of 422 Mh vaccination on PRRSV infection has been suggested from an experimental point of 423 view (Thacker et al., 2000), our study could not demonstrate such interaction.

424 The experimental design adopted in this trial probably underestimated the effect 425 of the vaccine, since it is known that vaccination is more effective when the whole 426 population is vaccinated than when only a part of the population is vaccinated 427 (Guadagnini et al., 1998). The main reason to use an experimental design where all the 428 treatment groups remained mixed was to rear all the animals with the same 429 environmental, feeding and management conditions. However, the presence of 430 unvaccinated pigs in the same pen/unit should increase Mh infectious pressure and, 431 therefore, the pig's potential exposure to the agent (Andreasen et al., 2001; Dawson et 432 al., 2002). In fact, the high prevalence of Mh in bronchus at fattening units in pigs from 433 all groups (from 79 to 86%) suggests that the infectious pressure in the batches studied 434 was considerably high. Therefore, under high Mh infectious pressure conditions, the 435 used vaccine resulted in earlier seroconversion and higher percentage of seropositive 436 pigs compared to control pigs. Moreover, reduction of EP-compatible gross lung lesions 437 and reduction of *Mh* prevalence at upper respiratory tract sites (nasal cavity and tonsil) 438 in slaughter pigs were observed when two doses of vaccine were administered.

439 Nevertheless, the present study was performed in one farrow-to-finish herd, and
440 therefore, results obtained may not be applicable to farms with different production
441 systems.

442

#### 443 Acknowledgements

The authors are very grateful to Jean Paul Cano, Gemma Castella, Ivan Díaz, Nilsa De Deus, Maria Fort, Llorenç Grau, José Gregorio, Álex Olvera, Humberto Ramírez and Mercè Roca, for helping in farm sampling. We would also thank the farmers Josep Palol and Simba for taking care of the pigs, Merche Mora, Eva Huerta and Mónica Pérez for technical assistance. And finally, we would like to express our thanks to Hipra for the technical support.


#### 450 References

- Andreasen, M., Mousing, J., Krogsgaard Thomsen, L., 2001, No simple association
  between time elapsed from seroconversion until slaughter and the extent of lung
  lesions in Danish swine. Prev Vet Med 52, 147-161.
- Baccaro, M.R., Hirose, F., Umehara, O., Goncalves, L.C., Doto, D.S., Paixao, R.,
  Shinya, L.T., Moreno, A.M., 2005, Comparative efficacy of two single-dose
  bacterins in the control of *Mycoplasma hyopneumoniae* in swine raised under
  commercial conditions in Brazil. Vet J 172, 526-531.
- 458 Calsamiglia, M., Collins, J.E., Pijoan, C., 2000, Correlation between the presence of
  459 enzootic pneumonia lesions and detection of *Mycoplasma hyopneumoniae* in
  460 bronchial swabs by PCR. Vet Microbiol 76, 299-303.
- 461 Calsamiglia, M., Pijoan, C., Trigo, A., 1999, Application of a nested polymerase chain
   462 reaction assay to detect *Mycoplasma hyopneumoniae* from nasal swabs. Swine
   463 Health and Production 7, 263-268.
- 464 Dawson, A., Harvey, R.E., Thevasagayam, S.J., Sherington, J., Peters, A.R., 2002,
  465 Studies of the field efficacy and safety of a single-dose *Mycoplasma*466 *hyopneumoniae* vaccine for pigs. Vet Rec 151, 535-538.
- Fano, E., Pijoan, C., Dee, S., 2006. Prevalence of *Mycoplasma hyopneumoniae* in piglets at weaning as a predictor of the severity of the disease in growing pigs.
  In: American Association of Swine Veterinarians, Kansas City, Missouri, p. 441.
- Guadagnini, P.F., Alborali, L.G., Meloni, S., Martelli, P., 1998. Herd health status in
  Finishers: lung lesions and productive performance after *Mycoplasma hyopneumoniae* vaccination. In: International Pig Veterinary Society Congress,
  (IPVS) Birmingham, 5-9 July, p. 283.

- Haesebrouck, F., Pasmans, F., Chiers, K., Maes, D., Ducatelle, R., Decostere, A., 2004,
  Efficacy of vaccines against bacterial diseases in swine: what can we expect?
  Vet Microbiol 100, 255-268.
- Hannan, P.C., Bhogal, B.S., Fish, J.P., 1982, Tylosin tartrate and tiamutilin effects on
  experimental piglet pneumonia induced with pneumonic pig lung homogenate
  containing mycoplasmas, bacteria and viruses. Res Vet Sci 33, 76-88.
- Jones, G.F., Rapp-Gabrielson, V., Wlike, R., Thacker, E., Thacker, B.J., Gergen, L.,
  Sweeney, D., Wasmoen, T., 2005, Intradermal vaccination for *Mycoplasma hyopneumoniae*. Swine Health and Production 13, 19-27.
- 484 Kyriakis, S.C., Alexopoulos, C., Vlemmas, J., Sarris, K., Lekkas, S., Koutsoviti485 Papadopoulou, M., Saoulidis, K., 2001, Field study on the efficacy of two
  486 different vaccination schedules with HYORESP in a *Mycoplasma*487 *hyopneumoniae*-infected commercial pig unit. J Vet Med B Infect Dis Vet
  488 Public Health 48, 675-684.
- Leon, E.A., Madec, F., Taylor, N.M., Kobisch, M., 2001, Seroepidemiology of
   *Mycoplasma hyopneumoniae* in pigs from farrow-to-finish farms. Vet Microbiol
   78, 331-341.
- Llopart, D., Casal, J., Clota, J., Navarra, I., March, R., Riera, P., Artigas, P., 2002,
  Evaluation of the field efficacy of a *Mycoplasma hyopneumoniae* vaccine in
  finishing pigs. The Pig Journal 49, 70-83.
- Maes, D., Deluyker, H., Verdonck, M., Castryck, F., Miry, C., Vrijens, B., Verbeke, W.,
  Viaene, J., de Kruif, A., 1999, Effect of vaccination against *Mycoplasma hyopneumoniae* in pig herds with an all-in/all-out production system. Vaccine
  17, 1024-1034.
- Martelli, P., Terreni, M., Guazzetti, S., Cavirani, S., 2006, Antibody Response to
  Mycoplasma hyopneumoniae Infection in Vaccinated Pigs with or without
  Maternal Antibodies induced by Sow Vaccination. J Vet Med B Infect Dis Vet
  Public Health 53, 229-233.
- Mateusen, B., Maes, D., Hoflack, G., Verdonck, M., de Kruif, A., 2001, A comparative
   study of the preventive use of tilmicosin phosphate (Pulmotil premix) and
   *Mycoplasma hyopneumoniae* vaccination in a pig herd with chronic respiratory
   disease. J Vet Med B Infect Dis Vet Public Health 48, 733-741.
- 507 Okada, M., Sakano, T., Senna, K., Maruyama, T., Murofushi, J., Okonogi, H., Sato, S.,
  508 1999, Evaluation of *Mycoplasma hyopneumoniae* inactivated vaccine in pigs
  509 under field conditions. J Vet Med Sci 61, 1131-1135.
- Pallares, F.J., Gomez, S., Ramis, G., Seva, J., Munoz, A., 2000, Vaccination against
  swine enzootic pneumonia in field conditions: effect on clinical, pathological,
  zootechnical and economic parameters. Vet Res 31, 573-582.
- Pommier, P., Keïta, A., Pagot, E., Walters, J.R., Flochlay, A., 2000. Eficacy of *Mycoplasma hyopneumoniae* vaccination in the control of enzootic pneumonia
  under field conditions in France. In: International Pig Veterinary Society, IPVS,
  Melbourne, Australia, 17-20 September 2000, p. 499.
- Ruiz, A., Batista, L., Pijoan, C., 2002. Effect of different vaccination protocols in
   *Mycoplasma hyopneumoniae* infection. In: International Pig Veterinary Society
   Congress Ames, Iowa, p. 334.
- Scheidt, A.B., Mayrose, V.B., Van Alstine, W.G., Clark, L.K., Cline, T.R., Einstein,
   M.E., 1994, The effects of vaccinating pigs for mycoplasmal pneumonia in a
   swine herd affected by enzootic pneumonia. Swine Health Prod 2, 7-11.

- Sibila, M., Calsamiglia, M., Segalés, J., Rosell, C., 2004, Association between
   *Mycoplasma hyopneumoniae* at different respiratory sites and presence of
   histopathological lung lesions. Vet Rec 155, 57-58.
- Sorensen, V., Barfod, K., Feld, N.C., 1992, Evaluation of a monoclonal blocking
   ELISA and IHA for antibodies to Mycoplasma hyopneumoniae in SPF-pig
   herds. Vet Rec 130, 488-490.
- 529 Thacker, E.L., 2006, Mycoplasmal Disease, In: Straw, B.E., Zimmermann, J.J.,
  530 D'Allaire, S., Taylor, D.J. (Eds.) Diseases of Swine. Iowa State University Press,
  531 Ames, pp. 701-717.
- Thacker, E.L., Thacker, B.J., Janke, B.H., 2001, Interaction between *Mycoplasma hyopneumoniae* and swine influenza virus. J Clin Microbiol 39, 2525-2530.
- Thacker, E.L., Thacker, B.J., Young, T.F., Halbur, P.G., 2000, Effect of vaccination on
  the potentiation of porcine reproductive and respiratory syndrome virus
  (PRRSV)-induced pneumonia by *Mycoplasma hyopneumoniae*. Vaccine 18,
  1244-1252.

**Fig. 1:** Percentage of Mh seropositive live pigs vaccinated with two doses (•) and one dose (•) of bacterin and control pigs ( $\blacktriangle$ ). Presence of antibodies against Mh were detected using a monoclonal blocking (ELISA CIVTEST SUIS® MYCOPLASMA HYOPNEUMONIAE, HIPRA [Girona], Spain) \*<sup>1</sup> Statistical significant difference (p <0.05) between one dose and control groups versus two dose group. \*<sup>2</sup> Statistical significant difference (p<0.05) between two dose group versus control group. \*<sup>3</sup> Statistical significant difference (p <0.05) between one dose and two dose groups versus control group.



1 **Table 1:** Number (percentages) of Mh nPCR detection at nasal cavities in live animals

	Weeks of age											
Treatments	1	3	6	9	12	15	18	22	25			
	4/182	5/176	5/148	12/133	33/110	28/97	17/78	26/56	8/31			
Two doses	(2.1)	(2.8)	(3.3) <sup>a,b</sup>	(9)	(30)	(28.8)	(21.8)	(46.4)	(25.8) <sup>a</sup>			
	3/176	5/162	11/140	8/127	32/109	26/93	18/77	20/60	16/34			
One Dose	(1.7)	(3)	(7.8) <sup>a</sup>	(6.3)	(29.3)	(27.9)	(23.3)	(33.3)	(47) <sup>a,b</sup>			
	1/184	9/163	3/147	8/130	34/113	32/98	24/80	19/59	22/36			
Control	(0.5)	(5.5)	(2.0) <sup>b</sup>	(6.1)	(30)	(32.6)	(30)	(32.2)	(61.1) <sup>b</sup>			
<b>T</b> ( <b>1</b>	8/542	19/501	19/435	28/390	99/332	86/288	59/235	65/175	46/101			
Total	(1.5)	(3.8)	(4.4)	(7.2)	(29.8)	(29.9)	(29.9)	(25.1)	(45.5)			
3	•	1	1			1	1	1	1			

2 out of the total pigs tested in each sampling day.

4 a,b Within a column, values with different bold superscript were significantly different (p

5 < 0.05)

- 6 **Table 2:** Number (percentages) of Mh nPCR detection at nasal cavities in
- 7 necropsied/slaughtered pigs out of the total pigs tested in each sampling day.
- 8

	Weeks of age										
Treatments	3	6	9	12	15	18	22	25	Total		
Two doses	1/13	1/13	1/13	2/12	7/16	7/17	10/19	8/31	37/134		
I wo uoses	(7.7)	(7.7)	(7.7)	(16.6)	(43.7)	(41.2)	(52.6)	(25.8) <sup>a</sup>	(27.6)		
One Dose	0/13	0/11	1/12	3/13	9/15	5/17	5/18	17/34	40/133		
	(0)	(0)	(8.3)	(23)	(60)	(29.4)	(27.7)	(50) <sup>a,b</sup>	(30.1)		
Control	0/11	0/12	1/12	3/12	8/17	5/17	7/17	21/36	45/134		
	(0)	(0)	(8.3)	(25)	(47)	(29.4)	(41.2)	(56.3) <sup>b</sup>	(33.5)		
Total	1/37	1/36	3/37	8/37	24/48	17/51	22/54	46/101	122/401		
	(2.7)	(2.7)	(8.1)	(21.6)	(50)	(33.3)	(40.7)	(44.6)	(30.4)		

10 <sup>a,b</sup> Within a column, values with different bold superscript were different (p < 0.05)

- 11 Table 3: Number (percentages) of Mh nPCR detection at bronchi in
- 12 necropsied/slaughtered pigs out of the total pigs tested in each sampling day..

		Weeks of age									
Treatments	3	6	9	12	15	18	22	25	Total		
T	1/13	1/13	1/13	6/12	12/16	14/17	14/19	27/32	76/135		
Two doses	(7.7)	(7.7)	(7.7)	(50)	(75)	(82)	(74)	(84)	(56)		
One Dose	0/13	0/11	0/12	6/13	12/15	12/17	15/18	27/34	72/133		
	(0)	(0)	(0)	(46)	(80)	(71)	(83)	(79)	(54)		
Control	1/13	0/12	1/12	5/12	14/17	13/17	13/17	32/37	79/137		
	(8)	(0)	(8)	(42)	(82)	(76)	(76)	(86)	(58)		
	2/38	1/36	2/37	17/37	38/48	39/51	42/54	86/103	227/404		
Total	(5.1)	(2.7)	(5.4)	(45.9)	(79.1)	(76.4)	(77.7)	(83.5)	(56.0)		

14

- 15
- 16 Table 4: Number (percentage) of Mh nPCR detection at tonsil in

	Weeks of age									
Treatments	3	6	9	12	15	18	22	25	Total	
Two doses	1/13	0/13	0/13	4/12	10/16	8/17	12/19	12/32	47/135	
I wo doses	(7.7)	(0)	(0)	(33.3)	(62.5)	(47.0)	(63.1)	(37.5) <sup>a</sup>	(34.8)	
One Dose	0/13	0/11	0/12	1/12	6/15	5/17	8/18	19/34	39/132	
	(0)	(0)	(0)	(7.7)	(40)	(29.4)	(44.4)	(55.8) <sup>a,b</sup>	(29.5)	
Control	0/12	1/12	0/11	1/12	8/17	5/16	9/17	26/37	50/134	
	(0)	(8.3)	(0)	(8.3)	(47)	(29.4)	(52.9)	(70.2) <sup>b</sup>	(37.3)	
<b>T</b> ( )	1/38	1/36	0/36	6/36	24/48	18/50	29/54	57/103	136/401	
Total	(2.6)	(2.7)	(0)	(16.6)	(50)	(36)	(55.7)	(55.3)	(33.9)	

17 necropsied/slaughtered pigs out of the total pigs tested in each sampling day.

18

19 <sup>a,b</sup> Within a column, values with different bold superscript were different (p < 0.05)

- Table 5: Median (min-max) of EP-compatible gross lung lesions (craneo-ventral pulmonary consolidation) in necropsied/slaughtered pigs. EP-compatible macroscopic lung lesion scoring was given from 1 to 5 points per lobe depending on the extension of these lesions. The maximum total score possible per lung was 35.
- 24

	Weeks of age											
Treatment	3	6	9	12	15	18	22	25				
T L	0.00	0.00	0.00	0.00	2.32	4.95	4.50	2.18				
Two doses	(0-4)	(0-6)	(0-18)	(0-6)	(0-29)	(0-22)	(0-19)	(0-18) <sup>a</sup>				
One Dose	0.00	0.00	0.00	0.00	4.85	5.86	4.41	2.42				
One Dose	(0-5)	(0-15)	(0-11)	(0-25)	(0-27)	(1-14)	(0-29)	(0-21) <sup>a,b</sup>				
	0.00	0.00	0.00	1	3.57	3.21	3.17	5.70				
Control	(0-7)	(0-3)	(0-3)	(0-15)	(0-12)	(0-27)	(0-19)	(0-28) <sup>b</sup>				

<sup>a,b</sup> Within a column, values with different bold superscript were significantly different (*p* 

26 < 0.05)

Table 6: Median (min-max) EP-compatible gross lung lesions (craneo-ventral pulmonary consolidation) of necropsied and slaughtered pigs depending on the nPCR results of nasal, bronchial and tonsillar swabs. EP-compatible macroscopic lung lesion scoring was given from 1 to 5 points per lobe depending on the extension of these lesions. The maximum total score possible per lung was 35.

32

Loca lizatio n	nPCR	n	Median Gross lung lesions (min-max)	Wilcoxon test P value
Nasal cavity	Negative	279	1.07 (0-29)	
	Positive	122	3.36 (0-28)	0.0003
Bronchus	Negative	176	0.00 (0-26)	
	Positive	225	3.99 (0-29)	0.0003
Tonsil	Negative	265	1.00 (0-29)	
	Positive	136	4.64 (0-27)	0.0001

33

Table 7: Number (percentages) of necropsied/slaughtered pigs showing EP-suggestive (3 or 4 histopathologic scores) microscopic lung lesions. Score 3 lesions included perivascular and peribronchiolar lymphoplasmacytic hyperplasia, pneumocyte type II hyperplasia and edema fluid in the alveolar spaces with neutrophils, macrophages and plasma cells. Score 4 was considered when score 3 lesions had evident peribronchial and perivascular lymphoid follicles.

40

	Weeks of age											
Treatment	3	6	9	12	15	18	22	25	Total			
T 1	0/13	3/13	6/13	6/12	9/16	13/17	18/19	28/32	80/135			
Two doses	(0)	(23)	(46)	(50)	(56)	(76)	(95)	(87)	(52.2)			
0 D	0/13	2/11	5/12	4/13	8/15	16/17	17/18	31/34	83/133			
One Dose	(0)	(18)	(42)	(31)	(53)	(94)	(94)	(91)	(62.4)			
Control	0/13	1/12	5/12	4/12	12/17	12/17	16/17	32/37	82/137			
Control	(0)	(8)	(41)	(33)	(70)	(71)	(94)	(86)	(59.8)			
Total	0/39	6/36	16/37	14/37	29/48	41/51	51/54	91/103	245/405			
	(0)	(16.6)	(43.2)	(37.8)	(60.4)	(80.3)	(94.4)	(88.3)	(60.4)			

41

42

43